The principles and major formats of protein microarray technologies and their applications in gastric cancer are summarized and current challenges and future directions for clinical translation are discussed.
Abstract
Gastric cancer remains a major cause of cancer-related mortality worldwide, largely due to late diagnosis and pronounced molecular heterogeneity. Although genomic and transcriptomic studies have advanced understanding of gastric tumor biology, they do not fully capture dynamic changes in protein expression, post-translational modifications, and signaling activity that directly regulate cellular function. High-throughput proteomic technologies, particularly protein microarrays, have emerged as powerful platforms for systematic protein profiling in complex biological samples. These technologies enable the simultaneous quantification of hundreds to thousands of proteins with high sensitivity and minimal sample requirements, supporting both discovery and translational research. Recent applications of protein microarrays in gastric cancer include biomarker discovery for early diagnosis, molecular subtyping, characterization of the tumor microenvironment, and assessment of therapeutic response. Multi-protein biomarker panels and integration with computational approaches have demonstrated improved diagnostic performance compared with conventional single-marker assays. In addition, proteomic profiling has provided insights into key signaling pathways and immune-related mechanisms underlying tumor progression and drug resistance. This review summarizes the principles and major formats of protein microarray technologies and highlights their applications in gastric cancer. Current challenges and future directions for clinical translation are also discussed.
An overview of recent progress in multi-omics approaches is provided and significant miRNA-, lncRNA-, and exosome-related biomarkers associated with the initiation, progression, and therapeutic response of breast cancer are emphasized.
Kamyar Bagheri, Amirhossein Saberi, Maryam Zand et al.· Cancer Treatment and Researc...· 0 citations
Genomic and DNA methylation-based analyses have transformed the classification of central nervous system (CNS) tumors by enabling robust molecular diagnosis and subclassification. However, these approaches primarily define tumor identity and do not directly capture the functional state of intracellular signaling networ...
Dennis Friedel, Rhaissa Ribeiro da Silva, Ivan Abdulrazak Ahmed et al.· Acta Neuropathologica· 0 citations
This study provided an accurate picture of the proteomic landscapes during the progression of carcinogenesis and identified several potential candidates as new biomarkers for CRC, and highlighted the potential of proteomic technology to elucidate clinically relevant cancer signatures.
Qi Zhang, Wen-Yuan Zhu, Jian-Guo Ji et al.· Clinical Proteomics· 0 citations
This review provides a comprehensive overview of MS-based proteomics applications in kidney disease research, covering progress in biomarker identification, pathogenic mechanism interrogation, and clinical translation, and addresses current challenges in clinical applications, including sample heterogeneity, data compl...
Ying-Ying Ling, Fei Cai, Ling Li et al.· Mass spectrometry reviews (P...· 0 citations
The increasing biological complexity and heterogeneity of cancer have driven a shift in oncology drug discovery from single-target approaches toward system-level strategies capable of capturing multilayered disease regulation. Multi-omics technologies, including genomics, transcriptomics, proteomics, metabolomics, epig...
Deval Koshti, N. Khandale, Jignesh Shah et al.· AAPS PharmSciTech· 0 citations
Investigation of MS-related prognostic genes and their potential biological relevance in CRC progression finds potential clues for future studies of CRC prognosis and MS-related tumor biology.